BD Medical Pharmaceutical systems

BD® Dual-Injection Syringe System is designed to enable dual-injection delivery of two liquid drug formulations while maintaining compatibility within standard prefillable syringes and autoinjectors. At the core of this system is a novel valve component that maintains physical separation of the two liquids...

ZebraSci – a BD Company – provides expert combination product testing and advisory services, supporting customers from concept to commercialization to ensure performance, compliance, and patient safety.
How can we partner with you to serve your combination product development needs?zebrasci.comsa...

BD’s Dual-Injection Syringe System enables two separate drug chambers to remain isolated until administration, simplifying co-delivery of combination therapies. Built on proven BD platforms, it supports standard fill-finish processes, reduces complexity, and helps accelerate time-to...

BD Libertas™ is a ready-to-use, prefilled wearable injector designed for large-volume biologics. With simple push-button activation, automated needle insertion and retraction, and clear visual and audible feedback, it offers a comfortable, hands-free experience for patients. Battery...

The fill/finish stage in pharmaceutical manufacturing is increasingly becoming a bottleneck for many companies. A McKinsey report states, “The world will need more sterile products than manufacturers have or can build capacity for.” Simultaneously, health authorities and regulators are intensifying their d...

The development of new parenteral biologics with high-volume, high-viscosity formulations (> 1 mL, >15 cP) is triggering the need for devices that can deliver these therapies with the ease, safety, and low injection time required for self-injection. As these formulations come to market, pharmaceutical and biotech companies must make critical device choices from an array of largely unproven options. The attachment discusses how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.  

Discover the article published in Drug Development & Delivery in October 2021 (Vol 21 No 7)...